In a case series of five patients with treatment-refractory antisynthetase syndrome and five patients with treatment-refractory systemic sclerosis, bispecific T cell engagers blinatumomab and teclistamab improved disease activity and were well tolerated.
- Christina Düsing
- Andrea-Hermina Györfi
- Jörg H. W. Distler